%0 Journal Article
%T 胃癌的治疗性免疫调节<br>Therapeutic Immunomodulation of Gastric Cancer
%A 邓莉莉
%A 沈存芳
%J Journal of Clinical Personalized Medicine
%P 315-322
%@ 2334-3443
%D 2024
%I Hans Publishing
%R 10.12677/jcpm.2024.32046
%X 胃癌是一种消化系统恶性肿瘤，是世界第六大最常见的癌症，也是与肿瘤疾病死亡的第二大原因。免疫治疗药物的出现和发展为胃癌患者带来了显著的生存优势，同时也对传统药物治疗模式提出了挑战。近年来，特别是免疫检查点抑制剂作为一种新兴的治疗方式，它通过阻断特定的信号通路，特别是CTLA4通路和PD-1/PD-L1通路发挥作用。本文主要概述了晚期GC免疫治疗的最新进展，包括免疫检查点抑制剂、癌症疫苗、血管内皮生长因子-A抑制剂和嵌合抗原受体T细胞治疗。<br />
Gastric cancer, a malignant tumor of the digestive system, is the sixth most common cancer in the world and the second leading cause of death associated with oncological disease. The emergence and development of immunotherapy drugs have brought significant survival advantages to gastric cancer patients, but also challenged the traditional drug treatment model. In recent years, immune checkpoint inhibitors in particular have emerged as an emerging therapeutic modus operandi, which work by blocking specific signaling pathways, especially the CTLA4 pathway and the PD-1/PD-L1 pathway. This article mainly reviews the recent advances in advanced GC immunotherapy, including immune checkpoint inhibitors, cancer vaccines, vascular endothelial growth factor-A inhibitors, and chimeric antigen receptor T cell therapy.
%K 胃癌，免疫治疗，免疫检查点抑制剂，PD-1，PD-L1，CTLA-4，治疗，生物标志物<br>Gastric Cancer
%K Immunotherapy
%K Immune Checkpoint Inhibitors
%K PD-1
%K PD-L1
%K CTLA-4
%K Treatment
%K Biomarkers
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=88911